-
2024-512676-36-00
10
2024-10-09
Langerhans Cell Histiocytosis
-
2023-510025-14-00
3
2024-10-08
Systemic Lupus Erythematosus
-
2024-511212-24-00
9
2024-10-07
Advanced solid tumors
-
2023-505739-12-01
5
2024-09-30
Chronic Inducible Urticaria (CINDU)
-
2023-510279-80-00
4
2024-09-25
Prurigo nodularis
-
2024-510923-20-00
4
2024-09-16
Metabolic Dysfunction-Associated Steatohepatitis
-
2023-508219-21-00
5
2024-09-12
BTC - Biliary Tract Cancer
-
2023-509190-23-00
5
2024-09-03
Atherosclerotic Cardiovascular Disease
Elevated lp(a)
-
2024-511260-84-00
4
2024-09-03
Atopic Dermatitis
-
2023-504922-20-00
5
2024-08-23
Hypercholesterolemia
-
2023-504331-41-00
5
2024-08-02
Respiratory tract diseases - Wheezing, Asthma
-
2023-506876-28-00
5
2024-08-01
The medical condition we are investigating is type 1 AMI (STEMI and NS
-
2023-509762-38-00
5
2024-08-01
Respiratory Syncytial Virus Infections
-
2023-507204-31-00
5
2024-07-26
Hidradenitis Suppurativa
-
2022-502954-15-00
4
2024-06-21
Idiopathic pulmonary fibrosis
-
2023-508235-31-00
5
2024-06-17
Atopic Dermatitis
-
2023-503666-23-00
5
2024-06-07
Neovascular age-related macular degeneration
-
2022-502781-24-01
5
2024-06-05
ASCVD - Atherosclerotic Cardiovascular Disease
-
2023-508359-38-00
5
2024-06-05
Early-stage Non-squamous Non-small Cell Lung Cancer
-
2023-505435-12-00
5
2024-06-04
Asthma
-
2023-508459-37-00
1
2024-05-28
HER2-positive advanced solid tumours
-
2023-506669-70-00
5
2024-04-30
Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
-
2022-502518-98-00
5
2024-04-26
nonsegmental vitiligo
-
2023-505928-59-00
5
2024-04-15
Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer